Company Active LTD

Company profile

Enterika Limited

UK company 13584572, incorporated on 25 August 2021.

Queen Mary University of London

Queen Mary University of London is an established university in London's vibrant East End committed to high-quality teaching and research; offering both undergraduate and postgraduate degrees.

Company number
13584572
Incorporated
25 Aug 2021
Companies House status
Active

Company identity

Founded / incorporated
25 August 2021

Company number 13584572

Verify at Companies House
Legal name
ENTERIKA LIMITED
Company type
Private Limited Company
Region
Unknown
Registered address
5 WALDEN STREET
QUEEN MARY ENTERPRISE
LONDON
LONDON
ENGLAND
E1 2EF
Insolvency history
No

Corporate ownership

Updated 07 Jul 2026 09:49

1 level 1 ultimate controller
1
Company Active LTD
Enterika Limited
CRN 13584572
2
Direct and ultimate controller Active ROYAL-CHARTER

Company events

Reference milestones and recent Companies House filing stream events.

5 events
07 Sep
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

31 Aug
2026

Accounts due

Accounts Due

Next accounts due date

24 Aug
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Aug
2024

Accounts filed

Accounts

Last accounts made up date

25 Aug
2021

Incorporated

Inception

Company registered at Companies House

Public funding

2 awards
First funded
2022
Funded years
2022, 2023
Age at first award
0 years

Projects

2023 Investment Accelerator Lead participant

Dosage study for validation of a novel weight loss treatment

1 Dec 2023 to 30 Nov 2024

Awarded
£50,000
Total cost £50,000

Reducing food intake by lowering appetite is critical for weight loss, an urgent public health issue that has resulted in a global obesity epidemic. Research by our scientific group led to a key discovery - a novel and effective means to reduce appetite in obese people, culminating in a series of international patents, and publication in a prestigious sci...

2022 Collaborative R&D Lead participant

Validation Of Novel Nutrient Formulation For Appetite Regulation

1 Aug 2022 to 31 Jan 2024

Awarded
£146,895
Total cost £209,850

Our scientific group has pioneered research on how our gut senses the contents of a meal since 1984\. This research has culminated in a major paper published this year showing our discovery of a novel and effective means to reduce appetite in obese people. Our company, Enterika, was set up to take this discovery to the market as a product that could then ...

Product types

Collaborative R&D Investment Accelerator